Staurosporine inhibits STA2-induced platelet aggregation by inhibition of myosin light-chain phosphorylation in rabbit washed platelets.
Takano
S
S
Department of Pharmacology, Fukushima Medical College, Japan.
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology; D007700:Kinetics; D009218:Myosins / Q000097:blood*; D010750:Phosphoproteins / Q000097:blood / Q000302:isolation & purification; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000097:blood; D047428:Protein Kinase Inhibitors; D011817:Rabbits; D019311:Staurosporine; D013928:Thromboxane A2 / Q000031:analogs & derivatives* / Q000494:pharmacology
D000470:Alkaloids; D007546:Isoquinolines; D010750:Phosphoproteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D013928:Thromboxane A2; C037866:STA 2; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D011493:Protein Kinase C; D009218:Myosins; D019311:Staurosporine